Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials

Abstract

Integrated data show that baricitinib is well-tolerated in EA patients with moderate-to-severely active RA in the context of demonstrated efficacy, which is generally consistent with safety results of the overall study population.